



MANHATTAN SCIENTIFICS, INC.

The Chrysler Bldg., 32nd Floor  
405 Lexington Ave.,  
New York, N.Y. 10174  
917.919.0370  
www.mhtx.com


# Investment Profile

OTC BB: MHTX

IR Contact: Frank N. Hawkins, Jr.  
Hawk Associates  
305.451.1888

February 25, 2010

## MHTX Acquires Exclusive Rights to Nanomedicine Technology for Early Cancer Detection and Treatment. Uses No Radiation and is 100x More Sensitive Than Existing Diagnostics



### Company Description

Manhattan Scientifics Inc. develops and nurtures financially promising technology companies with global application potential. The company and its affiliates now own a significant IP portfolio and patents in high-strength metals, early cancer detection, alternative energy, hydrogen fuel cells and computer 3D touch haptics.

The company's business model is to commercialize, bringing products to market to create profit for its shareholders through partnerships with manufacturers and licensees of its patents.

Manhattan Scientifics has enjoyed a special informal relationship and a successful history in tech-transfer from the Los Alamos National Laboratory (LANL) and the Sandia National Laboratory (SNL).

An example of this relationship was the seed funding and launch of Novint Technologies, which acquired the exclusive, perpetual, global license to the Haptics technology from Sandia National Labs and now trades as a listed company in the OTC BB under ticker symbol NVNT. For more information, visit <http://www.novint.com>.

### OTC BB: MHTX

Closing Price (02/25/10)	\$0.104
Market Cap.	\$41.21 mil.
52-Week Range	\$0.03 - \$0.19
Avg, Daily Volume (3 mo.)	408,000
Basic Shares	396 mil.
Est. Public Float	126 mil.
Insider Ownership	33%
Fiscal Year End	Dec. 31

### Projects

**Nanomedicine** - Manhattan Scientifics is collaborating with Dr. Edward Flynn, owner of Senior Scientific, to commercialize a nanomedicine technology - specifically a biomagnetic detection of cancer and other diseases through magnetic field sensors that make it possible to identify and image small clusters of cancer cells increasing the possibility of finding cancer at a much earlier stage than is currently possible.

**NanoTitanium** - Manhattan Scientifics owns

### Highlights

#### 02/25/10

Manhattan Scientifics acquires exclusive rights to nanomedicine technology for early cancer detection and treatment that uses no radiation

#### 11/16/09

Manhattan Scientifics reports first ever profitable quarter. Company will begin filing as "operating business."

#### 09/21/2009

Carpenter Technology to develop, market high-strength metals in licensing agreement with MHTX.

#### 7/8/2009

Manhattan Scientifics resumes trading on the OTC BB.

#### 2/11/2009

Manhattan Scientifics Completes \$1.0 Million Equity Raise.

#### 12/9/2008

FDA Approval Granted On New Titanium Dental Implant; Double-strength Metal Expected to Integrate Into Bone Up To 20 Times Faster; \$2 Billion Dental-Implant Market is Goal



INVESTOR RELATIONS COMMUNICATIONS

Tel: (305) 451-1888 • 227 Atlantic Blvd • Key Largo, Fla. 33037  
[manhattan.scientifics@hawkassociates.com](mailto:manhattan.scientifics@hawkassociates.com) • [www.hawkassociates.com](http://www.hawkassociates.com)

# Investment Profile

MHTX



MANHATTAN SCIENTIFICS, INC.

exclusive rights to the key patents and IP portfolio to produce and market NanoTitanium and other ultra fine grain nano-structured metals. The company has acquired Metallicum along with its patented rights for new ultra fine grain metals that may advance the transportation and medical device industry, emphasizing dental implants, cardiovascular stents and a wide range of prosthetic applications including artificial knees, shoulders, and hips.

NanoTitanium is highly compatible with bone and is thought to provide stronger, faster bonding with improved strength, biocompatibility, longer life and improved wear and tear.

In terms of transportation, NanoTitanium may profoundly impact today's fuel economy. This technology is expected to trim thousands of pounds from airplanes and hundreds of pounds from cars without sacrificing structural strength or adding significant cost.

## Alternative Energy Technologies -

Manhattan Scientifics is pursuing several potential MHTX owns the patents and IP technology for the award winning NovArs hydrogen powered fuel cell engine. Light weight and portable, it may be ideal to provide an inexpensive and environmentally friendly "green" system to drive scooters, bicycles, power tools, portable electronics, wheel chairs, golf carts and home emergency power.

**Haptics** - Manhattan Scientifics provided \$4.5 million seed funding to launch Novint Technologies Inc. The patented Novint Falcon, a computer game controller, enables the ability to touch and realistically feel images on a computer screen including texture, weight, motion and viscosity. The company is gaining recognition and growing rapidly, recently signing an agreement with Electronic Arts, whereby the company will create games compatible with the controller.

## Technology and Background

Manhattan Scientifics began as a technology incubator. The company has focused on acquiring several technologies in the fields of holographic data storage, water purification, alternative energy, advanced computer haptics and, most recently,

nanotechnology. The majority of MHTX's commercial technologies come from U.S. government laboratories in New Mexico.

## The Outlook

MHTX continues its role as pioneer in the fields of nano technology, alternative energy and advanced computing.

Carpenter Technology Corp. (CRS) will develop and market a new new class of high-strength metals under exclusive license to MHTX and Los Alamos National Labs. The contract includes minimum annual payments over a four year period with royalty payments as a percent of gross sales. The ultra fine grain metals have broad applications in medicine and industry. The agreement is providing positive cash flow and profitability to MHTX.

MHTX has acquired full commercial rights to the body of work of nuclear physicist Edward R. Flynn, Ph.D. and his company Senior Scientific LLC. His breakthrough technology focuses on the emerging field of nanomedicine, with emphasis on the early detection and localization of cancer and other diseases, providing image-guided therapy for treatment.

Early detection of cancer can be critical to effective treatment. Current mammography cannot detect a breast cancer tumor until it has grown to over ten million cells. Dr. Flynn's technology has proven the ability to detect breast cancer tumors while they are only 1% that large, resulting in an hundred-fold increase in sensitivity and early detection. The company is seeing partners to commercialize Dr. Flynn's technologies.

## Management Team

Chairman and CEO -

**Emmanuel (Manny) Tsoupanarias.**

Non-executive Chairman - **Marvin Maslow**

Special Counsel - **Larry Schatz, Esq.**

Director - **Leonard Friedman, Esq.**

Director - **Frank Georgiou**

Director - **Chris Theoharis**

## Scientific Advisory Board

### Dr. Terry Lowe

Co-inventor of the nano-structured metals process, president and chief scientist for the Metallicum unit of Manhattan Scientifics

### Dr. Martin Cooper

28 years chief technical officer with Motorola. "Father" of cellular telephone.

### Dr. Arthur Kaufman

co-founder of H-Power, a leader in the hydrogen fuel cell industry.

### Donald J. Sandstrom

42 years with Los Alamos National Laboratory. Materials Science Technology Division Leader.

### Dr. Arthur Koschany

Mid-Range Fuel Cell Scientist, Passau, Germany.

### Dr. Henry Rack

Professor of Materials Science & Engineering at Clemson University

## Website Information

Copies of MHTX press releases, current price quotes and other valuable information for investors may be found on the websites:

[www.mhtx.com](http://www.mhtx.com)

[www.hawkassociates.com](http://www.hawkassociates.com)

Company "units" or affiliates may be found at:

[www.novint.com](http://www.novint.com)

[www.energyrelateddevices.com](http://www.energyrelateddevices.com)

## Risk Factors

Access to sufficient capital to bring product to market; to defend its patents; to surpass its competitors. No significant revenue or earnings. Ability to recruit additional senior management. Potential technical obsolescence. Numerous well-capitalized competitors.